Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: first clinical and histopathological results.
In a first clinical trial with the apoptosis-inducing human antibody SC-1 eight patients with poorly differentiated stomach adenocarcinoma of diffuse-type received 20 or 30 mg of purified SC-1 antibody intravenously, followed 24 or 48 h later by gastrectomy and lymphadenectomy. In seven cases a significant induction of apoptotic activity was measured in primary tumors as compared with earlier biopsy material and in five patients a significant regression of tumor mass could be determined histopathologically. No toxic crossreactivity was observed with normal tissue or organs of patients.
Vollmers
H P
HP
Institut für Pathologie, Josef-Schneider-Str. 2, Würzburg, 97080, Germany.
Zimmermann
U
U
Krenn
V
V
Timmermann
W
W
Illert
B
B
Hensel
F
F
Hermann
R
R
Thiede
A
A
Wilhelm
M
M
Rückle-Lanz
H
H
Reindl
L
L
Müller-Hermelink
H K
HK
D000230:Adenocarcinoma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000302:isolation & purification / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000302:isolation & purification / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D003131:Combined Modality Therapy; D053938:DNA Fragmentation; D005260:Female; D005743:Gastrectomy; D006801:Humans; D007167:Immunotherapy; D008197:Lymph Node Excision; D008297:Male; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C111124:SC-1 monoclonal antibody